Jade Biosciences, Inc. (JBIO)

NCM – Real vaqt narxi. Valyuta: USD

25.23

+0.37 (1.49%)

Yopilishda: May 12, 2026, 4:00 PM EDT

07.05.2026

Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

SAN FRANCISCO and VANCOUVER, British Columbia, May 07, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced financial results for the first quarter ending March 31, 2026, and provided a corporate update.

23.04.2026

Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO and VANCOUVER, British Columbia, April 23, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that Jade's Board of Directors granted an equity award to Edward R. Conner, M.D.

22.04.2026

Jade Biosciences Appoints Edward R. Conner, M.D.

SAN FRANCISCO and VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the appointment of Edward R. Conner, M.D.

06.03.2026

Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

SAN FRANCISCO and VANCOUVER, British Columbia, March 06, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced financial results for the fourth quarter and full year ending December 31, 2025, and provided a corporate update.

27.02.2026

Jade Biosciences, Inc. (JBIO) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Prepared Remarks Transcript

11.02.2026

Jade Biosciences to Participate in Upcoming Conferences

SAN FRANCISCO and VANCOUVER, British Columbia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences:

16.01.2026

Jade Biosciences, Inc. (JBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Videolar

No Data

There is no data to display

Press-relizlar

07.05.2026

Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

23.04.2026

Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

22.04.2026

Jade Biosciences Appoints Edward R. Conner, M.D.

06.03.2026

Jade Biosciences, Inc. (JBIO)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Jade Biosciences, Inc. (JBIO)

Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jade Biosciences Appoints Edward R. Conner, M.D.

Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Jade Biosciences, Inc. (JBIO) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Prepared Remarks Transcript

Jade Biosciences to Participate in Upcoming Conferences

Jade Biosciences, Inc. (JBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Videolar

No Data

Press-relizlar

Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jade Biosciences Appoints Edward R. Conner, M.D.

Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jade Biosciences Appoints Edward R. Conner, M.D.

Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Jade Biosciences, Inc. (JBIO) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Prepared Remarks Transcript

Jade Biosciences to Participate in Upcoming Conferences

Jade Biosciences, Inc. (JBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Videolar

No Data

Press-relizlar

Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jade Biosciences Appoints Edward R. Conner, M.D.

Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Search stocks

Jade Biosciences, Inc. (JBIO)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Jade Biosciences, Inc. (JBIO)

Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jade Biosciences Appoints Edward R. Conner, M.D.

Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Jade Biosciences, Inc. (JBIO) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Prepared Remarks Transcript

Jade Biosciences to Participate in Upcoming Conferences

Jade Biosciences, Inc. (JBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Videolar

No Data

Press-relizlar

Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jade Biosciences Appoints Edward R. Conner, M.D.

Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jade Biosciences Appoints Edward R. Conner, M.D.

Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Jade Biosciences, Inc. (JBIO) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Prepared Remarks Transcript

Jade Biosciences to Participate in Upcoming Conferences

Jade Biosciences, Inc. (JBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Videolar

No Data

Press-relizlar

Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jade Biosciences Appoints Edward R. Conner, M.D.

Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update